Disease · HP_0001643

Patent ductus arteriosus

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Patent ductus arteriosus. Diseases, record HP_0001643. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0001643

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Patent ductus arteriosus
Open Targets ID: HP_0001643
Other names: Ductus arteriosus, PDA, Patent ductus Botalli, Persistent arterial duct, Persistent ductus arteriosus
Highest stage of its drugs: Approval, for 4 of its 17 drugs, from DailyMed, EMA Human Drugs and PMDA

Source Open Targets

Drugs17

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
IBUPROFEN	CHEMBL521	Small molecule	Approval	EMA Human Drugs	45	43	43	Drugs and targets
INDOMETHACIN	CHEMBL6	Small molecule	Approval	DailyMed	19	18	18	Drugs and targets
IBUPROFEN LYSINE	CHEMBL1201141	Small molecule	Approval	DailyMed and PMDA	3	1	1	Drugs and targets
ALPROSTADIL	CHEMBL495	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
ACETAMINOPHEN	CHEMBL112	Small molecule	Phase 3	ClinicalTrials.gov	26	26	26	Drugs and targets
CAFFEINE CITRATE	CHEMBL1200569	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
ERGOCALCIFEROL	CHEMBL1536	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
LEVOTHYROXINE	CHEMBL1624	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
PLATELET CONCENTRATE	CHEMBL2108774		Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
RETINOL	CHEMBL986	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 17

See all 17 drugs

Targets45

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PTGS1	Cyclooxygenase	5	Cyclooxygenase inhibitor	Approval	https://conductscience.org/library/genes/5742	Drugs and targets
PTGS2	Cyclooxygenase	5	Cyclooxygenase inhibitor	Approval	https://conductscience.org/library/genes/5743	Drugs and targets
ADRB1	Adrenergic receptor	3	Adrenergic receptor agonist; Beta-1 adrenergic receptor agonist	Unknown	https://conductscience.org/library/genes/153	Drugs and targets
ADORA2A	Adenosine A2 receptor	2	Adenosine A2 receptor antagonist; Adenosine receptor antagonist	Phase 3	https://conductscience.org/library/genes/135	Drugs and targets
ADORA2B	Adenosine A2 receptor	2	Adenosine A2 receptor antagonist; Adenosine receptor antagonist	Phase 3	https://conductscience.org/library/genes/136	Drugs and targets
ADRA1A	Adrenergic receptor	2	Adrenergic receptor agonist	Unknown	https://conductscience.org/library/genes/148	Drugs and targets
ADRA1B	Adrenergic receptor	2	Adrenergic receptor agonist	Unknown	https://conductscience.org/library/genes/147	Drugs and targets
ADRA1D	Adrenergic receptor	2	Adrenergic receptor agonist	Unknown	https://conductscience.org/library/genes/146	Drugs and targets
ADRA2A	Adrenergic receptor	2	Adrenergic receptor agonist	Unknown	https://conductscience.org/library/genes/150	Drugs and targets
ADRA2B	Adrenergic receptor	2	Adrenergic receptor agonist	Unknown	https://conductscience.org/library/genes/151	Drugs and targets

1 to 10 of 45

See all 45 targets

Trials62

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01958320	Early Treatment Versus Delayed Conservative Treatment of the Patent Ductus Arteriosus	Phase 2	202	2018-11-30	Patent Ductus Arteriosus, Surgery, Necrotizing Enterocolitis, Intestinal Perforation	IBUPROFEN	Its record names the disease	ClinicalTrials.gov
NCT00802685	Timing of PDA Closure and Respiratory Outcome in Premature Infants	Not applicable	105	2013-11-28	Patent Ductus Arteriosus	IBUPROFEN	Its record names the disease	ClinicalTrials.gov
NCT00833365	Early Versus Late Use of Ibuprofen for Patent Ductus Arteriosus (PDA) Closure	Not applicable	15	2016-07-04	Patent Ductus Arteriosus, Prematurity	IBUPROFEN	Its record names the disease	ClinicalTrials.gov
NCT03701074	Randomized Controlled Trial to Evaluate the Safety and Efficacy of Acetaminophen in Preterm Infants Used in Combination With Ibuprofen for Closure of the Ductus Arteriosus	Phase 2	1	2021-05-11	Patent Ductus Arteriosus, Preterm Infant, Bronchopulmonary Dysplasia	ACETAMINOPHEN, IBUPROFEN	Its record names the disease	ClinicalTrials.gov
NCT04347720	Canadian National PDA Treatment Study		1,663		Patent Ductus Arteriosus, Extreme Prematurity	ACETAMINOPHEN, IBUPROFEN, INDOMETHACIN	Its record names the disease	ClinicalTrials.gov
NCT07533721	Ibuprofen vs Expectant Management for hsPDA in Preterm Infants: Retrospective Cohort		541		Patent Ductus Arteriosus, Infant, Premature	IBUPROFEN	Its record names the disease	ClinicalTrials.gov
NCT04397913	Population Pharmacokinetics and Dosage Individualization of Paracetamol and Ibuprofen in Children With PDA		500		Patent Ductus Arteriosus	ACETAMINOPHEN, IBUPROFEN	Its record names the disease	ClinicalTrials.gov
NCT01630278	Early Ibuprofen Treatment of Patent Ductus Arteriosus (PDA) in Premature Infants (TRIOCAPI)	Phase 3	363		Patent Ductus Arteriosus	IBUPROFEN	Its record names the disease	ClinicalTrials.gov
NCT05340582	Co-administration of Acetaminophen With Ibuprofen to Improve Duct-Related Outcomes in Extremely Premature Infants	Phase 2	310		Patent Ductus Arteriosus After Premature Birth	ACETAMINOPHEN, IBUPROFEN	Its record names the disease	ClinicalTrials.gov
NCT04060381	Myocardial Deformation Before and After Birth		300		Myocardial Dysfunction, Newborn Morbidity, Maternal Obesity	DOPAMINE, EPINEPHRINE, IBUPROFEN, NOREPINEPHRINE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 62

See all 62 trials

Comparisons in its trials15

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Early Treatment vs Conservative Treatment: Incidence of Necrotizing Enterocolitis or Spontaneous Perforation	17 of 104	19 of 98	202	NCT01958320	Trial comparisons
Early Treatment vs Conservative Treatment: the Incidence of Persistent Moderate-to-large PDA Shunt 10 Days After Enrollment	43 of 104	78 of 98	202	NCT01958320	Trial comparisons
Early Treatment vs Conservative Treatment: Incidence of Bacteremia	31 of 104	21 of 98	202	NCT01958320	Trial comparisons
Early Treatment vs Conservative Treatment: the Incidence of Rescue Treatment Eligibility Criteria Met	32 of 104	61 of 98	202	NCT01958320	Trial comparisons
Early Treatment vs Conservative Treatment: Incidence of Pulmonary Hemorrhage	2 of 104	2 of 98	202	NCT01958320	Trial comparisons
Early Treatment vs Conservative Treatment: Incidence of Death	20 of 104	10 of 98	202	NCT01958320	Trial comparisons
Early Treatment vs Conservative Treatment: Number of Infants Who Received Dopamine for ≥3 Days	14 of 104	25 of 98	202	NCT01958320	Trial comparisons
Early Treatment vs Conservative Treatment: Number of Infants Receiving ≥ 14 Days of Diuretic Treatment	36 of 104	45 of 98	202	NCT01958320	Trial comparisons
Early Treatment vs Conservative Treatment: Incidence of Bronchopulmonary Dysplasia or Death	60 of 104	56 of 98	202	NCT01958320	Trial comparisons
Early Treatment vs Conservative Treatment: deaths from any cause	20 of 104	10 of 98	202	NCT01958320	Trial comparisons

1 to 10 of 15

See all 15 comparisons in its trials

Papers from its trials61

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
36477458	RESULT	1	PubMed
33307111	RESULT	1	PubMed
30340932	RESULT	1	PubMed
26951240	RESULT	1	PubMed
26672023	RESULT	1	PubMed
26283668	RESULT	2	PubMed
26244949	RESULT	1	PubMed
26168357	RESULT	1	PubMed
25835756	RESULT	1	PubMed
25653299	RESULT	1	PubMed

1 to 10 of 61

See all 61 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/HP_0001643

GET https://conductscience.org/api/diseases/v1/HP_0001643/targets?page=2

API reference For AI assistants